|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Research and development | |||||
| Research and development related success payments and contingent consideration | |||||
| General and administrative | |||||
| Impairment of long-lived assets | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Interest income, net | |||||
| Other income (expense), net | |||||
| Benefit from income taxes | |||||
| Net loss | |||||
| Net loss per common share - basic | |||||
| Net loss per common share - diluted | |||||
| Weighted-average number of common shares - basic | |||||
| Weighted-average number of common shares - diluted | |||||
Loading...